|
Mar 13
|
Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?
|
|
Mar 12
|
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
|
|
Mar 12
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Mar 1
|
Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?
|
|
Feb 28
|
Exelixis focuses on future growth despite COSMIC-313 trial challenges
|
|
Feb 26
|
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors
|
|
Feb 25
|
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
|
|
Feb 25
|
Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia
|
|
Feb 24
|
EXEL or TECH: Which Is the Better Value Stock Right Now?
|
|
Feb 23
|
Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks
|
|
Feb 21
|
Why Exelixis Stock Trounced the Market on Thursday
|
|
Feb 21
|
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
|
|
Feb 21
|
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
|
|
Feb 20
|
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
|
|
Feb 20
|
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
|
|
Feb 20
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
Feb 18
|
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
|
|
Feb 17
|
International Markets and Exelixis (EXEL): A Deep Dive for Investors
|
|
Feb 17
|
Five-year results see Exelixis’ RCC therapy extending overall survival
|
|
Feb 16
|
Exelixis Full Year 2024 Earnings: EPS Beats Expectations
|